Current stock page

Catalysts

CYTK Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

CYTKCytokinetics, Incorporated

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$56.13−$0.03 (−0.05%)

Latest quote

  • Momentum
    28
  • Value
    41
  • Quality
    46
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 23, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 40/100

Momentum 28/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 26.22%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 28/100AIQ Edge 2/10 Relative Laggard
Beat rate
63%
5 of 8 reported periods
Average surprise
-3.4%
Across covered historical reports
Latest result
+4.2%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$1.43-$1.37+4.2%$41.88M$47.56M
Aug 6, 2026—-$1.63-$1.50+8.0%$17.59M$28.62M
May 5, 2026—-$1.67-$1.67+0.0%$8.52M$19.36M
Feb 24, 2026—-$1.48-$1.50-1.4%$6.93M$17.76M
Nov 5, 2025—-$1.59-$2.55-60.4%$6.05M$1.94M
Aug 7, 2025—-$1.34-$1.12+16.4%$2.07M$66.77M
May 6, 2025—-$1.41-$1.36+3.5%$2.79M$1.58M
Feb 27, 2025—-$1.29-$1.26+2.3%$14.26M$16.93M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
20
Buy
2
Hold
12-month analyst target
$99.33
+76.97% versus current price
Based on 22 analyst observations. Targets are estimates, not predictions.
Low target
$81.00
+44.31% vs latest price
Average target
$99.33
+76.97% vs latest price
High target
$113.00
+101.32% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 23, 2027

Next known earnings or reporting date.

EPS estimate-$1.41

Current analyst expectation for the upcoming report.

Revenue estimate$64.28M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score28

Where event reaction would show up first.

AIQ score40/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
22
Average target
$99.33
Target upside
76.97%
Target range
$81.00 - $113.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Nov 9, 2026

Cytokinetics, Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CYTK) 2026-11-08

2026-11-08. The following slide deck was published by Cytokinetics, Incorporated in conjunction with their 2026 Q3 earnings call.

seekingalpha.com · Nov 5, 2026

Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript

Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call November 4, 2026 4:30 PM ESTCompany ParticipantsDiane Weiser - Senior Vice President of Corporate...

finance.yahoo.com · Sep 23, 2026

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

gurufocus.com · Sep 14, 2026

Cytokinetics, Incorporated at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2026 / 11:45AM GMTMaxwell Skor - Morgan Stanley - Moderator Great. Thank you everyone for joining. I am Max Skor, a biotech analyst with Morgan Stanley.

insidermonkey.com · Sep 8, 2026

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved...

Open full news and sentiment

CYTK Catalysts FAQ

What are the next catalysts for CYTK stock?

CYTK's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move CYTK stock?

Upcoming events that could move CYTK include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could CYTK's next earnings report affect the stock?

CYTK's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive CYTK stock higher?

CYTK could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt CYTK stock?

CYTK could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.